Background. Fibrosis in lymph nodes may limit CD4 + T-cell recovery, and lymph node and adipose tissue fibrosis may contribute to inflammation and comorbidities despite antiretroviral therapy (ART). We hypothesized that the angiotensin receptor blocker and peroxisome proliferator-activated receptor γ agonist telmisartan would decrease lymph node or adipose tissue fibrosis in treated human immunodeficiency virus type 1 (HIV) infection.
. Lipopolysaccharide, which is increased in HIV-infected persons because of gut barrier breach, triggers adipose tissue inflammation and fibrosis [15] . Finally, activated immune cells in adipose tissue surrounding lymph nodes may contribute to or reflect local inflammation [16] , perpetuating fibrosis. Thus, an intervention to decrease lymph node and adipose tissue fibrosis may improve clinical outcomes in HIV infection.
Angiotensin II signaling through the angiotensin II type 1 receptor likely enhances TGF-β production and signaling [17] [18] [19] [20] . To date, the effects of angiotensin receptor blockers (ARBs) on TGF-β-mediated tissue fibrosis have not been studied in HIVinfected persons receiving ART. Telmisartan is an ARB and a partial peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, with potential antiinflammatory and antifibrotic effects [21] [22] [23] [24] [25] .
In this randomized, open-label, 2-arm, pilot study, we added telmisartan or no study drug to continued ART to test the hypothesis that 48 weeks of telmisartan treatment will decrease lymph node and/or adipose tissue fibrosis in HIV-infected adults receiving suppressive ART.
METHODS
Institutional review boards at each site approved the study. All participants provided written informed consent prior to initiation of study procedures.
Study Design
AIDS Clinical Trials Group protocol A5317 (clinical trials registration 01928927) was a 48-week, 2-step, open-label, randomized, controlled trial of the effects of continued ART plus telmisartan versus continued ART alone on lymph node and/or adipose tissue fibrosis. Eligibility criteria included HIV infection, age ≥18 years, virologic suppression during ART for ≥48 weeks before study entry, HIV RNA load of <50 copies/mL at screening, no change in ART for 12 weeks before study entry, body mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared) of [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , systolic blood pressure of ≤160 mm Hg, and diastolic blood pressure of ≤100 mm Hg. Exclusion criteria included known renal artery stenosis, cirrhosis or advanced liver disease, decompensated congestive heart failure, unstable coronary artery disease, bleeding disorder/coagulopathy, heritable connective tissue disorders, history of angiotensin-converting enzyme inhibitor or ARB intolerance, use of anticoagulants except aspirin, need for regular potassium supplementation, or use of thiazolidinedione, ARB, or angiotensin-converting enzyme inhibitor in the 24 weeks before study entry.
In step 1, participants who met eligibility criteria underwent inguinal lymph node and subcutaneous abdominal adipose tissue biopsies. Participants with sufficient adipose and/ or lymph node biopsy specimens entered step 2 and were randomized 2:1 to receive telmisartan or no study drug. A 40-mg daily dose of telmisartan was given during weeks 0-4, and an 80-mg daily dose was given during weeks 5-48. Participants in the control arm received no study drug but underwent all study evaluations. All participants were instructed to continue ART throughout the study period. Follow-up inguinal lymph node and subcutaneous abdominal adipose tissue biopsies were performed at week 48. Clinical and safety evaluations were performed at weeks 0, 4, 12, 24, 36, and 48.
Lymph Node Tissue Specimen Analysis
Collagen I (mouse anti-human collagen I [clone COL-1]; SigmaAldrich, St. Louis, MO), fibronectin (mouse anti-fibronectin ; Thermo Fisher Scientific, Waltham, MA), and phosphorylated SMAD3 (pSMAD3; rabbit anti-Smad3 [phospho S423 + S425; EP823Y]; Abcam, Cambridge, MA) immunohistochemical staining was performed on formalin-fixed, paraffin-embedded lymph node tissue specimens [26] . Slides were scanned at 400× using the Aperio AT2 System (Leica Biosystems, Vista, CA). Representative regions of interest (0.25 mm 2 ) were identified, and high-resolution images were extracted from whole-tissue scans. The percentage of the lymph node T-cell zone area staining for collagen I, fibronectin, or pSMAD3 was quantified using Photoshop (CS5 and CS6; Adobe Systems, San Jose, CA), Noiseware 5 (Imagenomic, Alexandria, VA; for noise reduction), and Fovea Pro beta 5 (Reindeer Graphics, Asheville, NC) image analysis tools.
Adipose Tissue Specimen Analysis
Formalin-fixed, paraffin-embedded adipose tissue slides were stained for collagens I and VI (Santa Cruz Biotechnology, Dallas, TX) and fibronectin (Abcam). Slides were digitized on a ScanScope AT (Leica Biosystems). Morphometric analysis was performed with Tissue Studio (Definiens, Parsippany, NJ) to determine the percentage of the area stained by collagen I, collagen VI, and fibronectin, using a nonbiased method. A stain-specific algorithm was created using the predefined marker area detection module and classification tool. Thresholds were set to classify individual stains over the entire tissue area.
All staining and analysis for lymph node and adipose tissue were performed with investigators blinded to the study group.
Statistical Analysis
The co-primary outcome measures were between-group 48-week changes in the percentage of the areas of lymph node and adipose tissue specimens in which collagen I was deposited (hereafter, the "percentage deposition"). An absolute decrease in lymph node fibrosis of 4% is expected to correlate with an increase of 75 CD4 + T cells/mm 3 (based on an estimated baseline CD4 + T-cell count of 200 cells/mm 3 and 10% lymph node fibrosis) [6, 27] and was the predicted effect size for this study. The assessment of subcutaneous adipose tissue fibrosis, which has not been described in HIV infection outside of lipodystrophy, was exploratory, with the same desired effect size (4 percentage points) used. Thirty-six participants in the telmisartan arm and 18 in the control arm provided 90% power to detect an absolute between-group difference of ≥4% in collagen I percentage deposition over 48 weeks, allowing for ≤25% loss to follow-up and/or missing data (2-sided α = 0.05).
The primary analysis was per protocol and limited to participants who had paired biopsy data, continued to receive study treatment until ≤5 days of the week 48 biopsy (in the telmisartan arm only), and did not change ART or have virologic failure. All analyses comparing changes in continuous outcome measures between study arms at a postbaseline time point(s) used an equivalent version of the Wilcoxon rank sum statistic. We estimated the probability (θ) that the likelihood an outcome in the telmisartan arm was less than or equal to that in the control arm [28] by using the θ estimate (with 95% confidence intervals [CIs]) and corresponding P values. The null hypothesis was a θ of 0.5, with a θ of >0.5 indicating a less likely outcome in the telmisartan arm. Measurements below (above) assay limits were analyzed as the lowest (highest) rank. To assess differential treatment effects on the co-primary outcome measures, θ was estimated within independent participant subgroups and compared across subgroups, using linear contrasts.
The safety analysis compares the highest-grade primary event between study arms, using the Wilcoxon rank sum test. All statistical tests were 2-sided, with a nominal α level of 0.05 and no adjustment for multiple testing.
RESULTS

Participant Characteristics
Enrollment occurred during January 2014-April 2015 at 11 US sites. Fifty-eight participants entered step 1 and underwent biopsy ( Figure 1 ). Forty-four participants had adequate lymph node and/ or adipose tissue biopsy specimens and entered step 2. Of these, 93% were men, 48% were black or Hispanic, the median age was 48 years, the BMI was 25, and the median CD4 + T-cell count was 588 cells/mm 3 (Table 1) . Eighty-nine percent received nucleoside reverse transcriptase inhibitors (NRTIs; 70% received tenofovir), 39% received non-NRTIs, 55% received protease inhibitors (PIs), and 32% received integrase strand transfer inhibitors (INSTIs). All INSTI recipients were randomized to the telmisartan arm by chance, but ART use was otherwise balanced between arms. Eight had an HIV-1 RNA load of >40 copies/mL at entry (median, 151 copies/mL) despite an undetectable HIV-1 RNA load (<50 copies/mL) at screening. All but 1 participant with detectable HIV RNA at entry experienced resuppression of the viral load to <200 copies/mL throughout the follow-up period. This participant was removed from the analysis. Prohibited medications were used by 2 participants in the telmisartan arm (1 used deserpidine during weeks 3-38 and methylprednisolone acetate once in week 44, and the other used deserpidine starting in week 37) and 3 in the control arm (1 used lisinopril during weeks 28-36, 1 used lisinopril starting in week 11, and 1 used deserpidine once in week 44).
Three participants (10%) in the telmisartan arm did not complete treatment and were excluded from the per-protocol analysis: 1 developed a grade 4 increase in transaminase levels unrelated to study treatment and stopped ART, 1 withdrew consent, and 1 was lost to follow-up. One participant with a week 48 biopsy performed out of window and 3 without week 48 biopsies were also excluded. In the control arm, one participant did not return to clinic, and another participant had no week 48 biopsy. Thus, 35 participants (22 in the telmisartan group and 13 in the control group) were included in the per-protocol analysis. Pill counts suggested excellent adherence, except 1 participant missed treatment on 2 days (during week 6) and 12 days (during weeks 14-16), 1 missed treatment on 5 days (during weeks [11] [12] , and 1 missed treatment during 2 weeks. Baseline characteristics of the per-protocol population were similar to those of the randomized study population (data not shown).
Lymph Node Fibrosis
The median baseline collagen I percentage deposition in inguinal lymph node specimens was 13.7% (interquartile range The median baseline percentage deposition of pSMAD3, a surrogate marker of TGF-β signaling [29] , was 1.4% (IQR, 0.9%-2.8%) overall. By week 48, this value changed by a median of −0.5 percentage points (IQR, −2.1-0.3 percentage points; P = .04) overall, by −0.47 percentage points (IQR, −1.33-0.46 percentage points; P = .28) in the telmisartan group, and by −0.62 percentage points (IQR, −2.10-0.08 percentage points; P = .08) in the control group ( Figure 3C ). Telmisartan did not attenuate pSMAD3 deposition more than ART alone (θ = 0.46 [95% CI, .25-.67]; P = .69), consistent with telmisartan's lack of effect on collagen I deposition. However, decreases in pSMAD3 deposition correlated with decreases in collagen I deposition (r = 0.48; P = .01). Thus, lymph node TGF-β signaling decreased with continued ART, with no additional decrease with telmisartan therapy.
Adipose Tissue Fibrosis
The median baseline collagen I percentage deposition in subcutaneous lower abdominal adipose tissue was 1.9% (IQR, 0.4%-3.4%) overall, with a lower median value in the telmisartan group (1.3% [IQR, 0.3%-2.6%]) as compared to the control group (2.8% [IQR, 1.6%-3.7%]; between-group P = .06; Figure 2C , 2D, and 4A Figure 1 . Cohort diagram. Participants receiving suppressive antiretroviral therapy (ART) were enrolled into step 1 and underwent lymph node (LN) and adipose tissue biopsies. If adequate tissue specimens were obtained, they were enrolled into step 2 and randomized to receive telmisartan therapy or no additional drug. All participants were instructed to continue ART. Some samples were of insufficient quantity or quality for immunohistochemical analysis for the various markers. LN, lymph node; pSMAD3, phosphorylated SMAD3. P = .001) overall, with values of −1.1 percentage points (IQR, −2.1-0 percentage points; P = .02) in the telmisartan arm and −2.2 percentage points (IQR, −3.5-0 percentage points; P = .03) in the control arm and no significant between-arm difference (θ = 0.37 [95% CI, .14-.60]; P = .27). In sum, adipose tissue collagen I deposition significantly decreased with continued ART alone, with no additional benefit from telmisartan therapy.
Collagen VI, a major component of fibrotic adipose tissue (primarily studied in obesity [30] ), followed a similar pattern ( Figure 4B ). The median baseline collagen VI percentage deposition was 3.5% (IQR, 2.5%-5.3%) overall, with values of 3.2% (IQR, 2.2%-4.7%) in the telmisartan arm and 4.2% (IQR, 2.9%-5.3%) in the control arm (between-group P = .15). Over 48 weeks, the collagen VI percentage deposition changed significantly in both arms, with a median change of −1. The median baseline fibronectin percentage deposition was lower in the telmisartan arm as compared to the control arm, with values of 3.7% (IQR, 1.2%-6.4%) overall, 2.1% (IQR, 1.0%-5.6%) in the telmisartan arm, and 6.1% (IQR, 2.9%-8.6%) in the control arm (between-group P = .05; Figure 4C ). The fibronectin percentage deposition significantly declined over 48 weeks, with a median change of −2.4 percentage points (IQR, −5.5-0.1 percentage points; P < .001) overall, −0.8 percentage points (IQR, −4.0-0.5 percentage points; P = .05) in the telmisartan group, and −4.0 percentage points (IQR, −6.0 to −1.6 percentage points; P = .005) in the control group. Telmisartan therapy had no apparent impact on fibronectin deposition in adipose tissue (θ = 0.36 [95% CI, .16-.56]; P = .17).
Secondary Analyses
Overall, telmisartan treatment did not affect collagen I deposition in lymph node or adipose tissues, after stratifying by ART class, statin use, or baseline CD4 + T-cell count. Participants with CD4 + T-cell counts below the median value (ie, 572 cells/ mm 3 ) had statistically significant changes in lymph node collagen I percentage deposition (median −8.6 percentage points [IQR, −11.5-1.7 percentage points]; P = .04), which were not observed among participants with higher CD4 + T-cell counts (0.1 percentage points [IQR, −5.6-6.4 percentage points]). Changes in adipose tissue collagen I percentage deposition were smaller for participants with excess adiposity (BMI, ≥30; waist circumference, ≥95 cm for men and ≥94 cm for women, and/or waist-to-hip ratio of ≥0.94 for men and 0.88 for women), with a median of −0.4 percentage points (IQR, −1.6-1.0 percentage points; P = .54) among participants with excess adiposity, compared with −1.8 percentage points (IQR, −2.9 to −1.1 percentage points; P < .001) among those without excess adiposity. As PI therapy has been associated with adipose tissue inflammation, PPAR-γ suppression, and renin angiotensin system activation [31] [32] [33] [34] , we hypothesized that telmisartan therapy may affect participants receiving PIs differently. Indeed, the adipose tissue collagen I percentage deposition improved more after 48 weeks in PI-treated participants who received telmisartan therapy median (change, −1. A, Collagen I deposition in LN specimens was dynamic, with most participants experiencing a decrease regardless of study arm. B, LN fibronectin deposition increased in the control arm but not in the telmisartan arm. C, Phosphorylated SMAD3 (pSMAD3), a marker of transforming growth factor β signaling, decreased with continued ART, with no additional decrease with telmisartan. No significant differences were seen in changes over time between telmisartan and control groups. Within-group changes over time were secondary end points. Each line represents a single participant. The median value for each tissue at each time point is indicated at the top of each figure. The number of participants with evaluable samples at each time point for each marker is indicated at the bottom of each figure. P values reflect within-arm differences between weeks 0 and 48 and were determined by the Wilcoxon signed rank test. lipoprotein cholesterol level, triglycerides level, waist circumference, waist-to-hip ratio, or percentage of participants with metabolic syndrome, did not change significantly during the study, and telmisartan therapy had no significant effect on these parameters (data not shown). Telmisartan treatment significantly lowered blood pressure: the median change in systolic blood pressure 
Adverse Events
All randomized participants were included in the safety analysis. Telmisartan therapy was well tolerated. Five participants developed grade ≥3 adverse events, none of which were deemed related to study treatment ( Table 2) . No episodes of hypotension (symptomatic or asymptomatic) occurred.
DISCUSSION
Lymphoid tissue fibrosis occurs early in HIV infection, is associated with CD4 + T-cell depletion, and was previously thought to persist despite suppressive ART [36] [37] [38] . Adipose tissue fibrosis has been described primarily in obesity, where it can contribute to metabolic dysfunction, tissue hypoxia, and an ongoing, proinflammatory state [30, [39] [40] [41] . In HIV-infected persons, adipose tissue fibrosis has only been described in clinically significant lipoatrophy and dorsocervical fat accumulation [42, 43] . Thus, in the general population, tissue fibrosis is considered a response to a pathologic state or tissue dysfunction. Since chronic inflammation and immune activation persist despite suppressive ART, we hypothesized that lymph node and subcutaneous adipose tissue fibrosis are prevalent in HIVinfected adults receiving suppressive ART and that treatment with telmisartan, an ARB and PPAR-γ agonist with putative antifibrotic properties, would attenuate lymph node and adipose tissue fibrosis as compared to suppressive ART alone. This randomized trial documented several important, novel findings. First, subcutaneous adipose tissue fibrosis exists in HIV-infected adults outside of obesity and clinically significant lipodystrophy, a finding that may help explain metabolic disturbances in HIV-infected adults. Additionally, (1) adipose tissue collagen I, collagen VI, and fibronectin deposition decreased with continued ART alone; (2) continued ART decreased lymph node collagen I deposition among participants with lower baseline CD4 + T-cell counts; and (3) telmisartan therapy had no additional impact on collagen I deposition in lymph nodes or adipose tissue or on fibronectin or collagen VI deposition in adipose tissue in HIV-infected adults, compared with continued ART alone.
Previous studies of lymphoid tissue fibrosis have demonstrated no effect of ART but have only evaluated up to 1 year of treatment [37, 44, 45] . Thus, fibrosis may be stable early after starting ART, but continued suppressive ART may eventually permit resumption of wound healing processes and modest fibrosis reversal. The stimulus for this transition to improved wound healing/fibrosis reversal is unknown, but possibilities include insufficient local viral stimulus, reduced microbial or other profibrotic stimuli, and immune system alterations. Importantly, the percentage improvement in tissue fibrosis needed to exert a clinical benefit is also unknown. Given our small sample size and heterogeneous population and results, additional studies are needed.
Telmisartan's lack of additional benefit against fibrosis in this study may be multifactorial. The observed declines in collagen I, collagen VI, and/or fibronectin deposition with ART alone suggest that antifibrotic pathways were activated relative to those closer to ART initiation, consistent with suppression of TGF-β signaling. The observed decreases in pSMAD3 deposition reflect further suppression of TGF-β signaling at week 48 as compared to week 0, supporting the hypothesis of antifibrotic pathway activation with continued ART alone. Consequently, blocking TGF-β signaling with telmisartan therapy may not have had an additional impact. Alternatively, although TGF-β upregulation has been documented in fibrotic lymphoid tissue in a simian immunodeficiency virus model [5] , whether TGF-β-independent pathways, such as interleukin 13 or interleukin 33 signaling, contribute is unknown. Similarly, continued suppression of HIV replication may have resulted in minimal residual tissue inflammation, rendering telmisartan's antiinflammatory properties inconsequential. Participants with lower CD4 + T-cell counts, who may have greater systemic immune activation [46] , had the greatest declines in lymph node collagen I deposition, possibly because of the antiinflammatory properties of telmisartan. Similarly, participants receiving PIs may have had greater adipose tissue inflammation, making them more susceptible to telmisartan's antiinflammatory benefits.
This study had several limitations. First, the study was designed to provide 90% power to detect a 4-percentage-point change in collagen I deposition, which required 39 participants. With 35 participants in the per-protocol analysis, the study was underpowered for all end points. Nonetheless, no trend toward a benefit of adding telmisartan to ART was observed in lymph node or adipose tissue. Second, both immunohistochemistry laboratories were blinded to group but not time point, so some bias could have been introduced. The lack of placebo and numerous comparisons made may have also introduced type 1 error. Third, participants had high median CD4 + T-cell counts, were overwhelmingly male, and were primarily nonobese, possibly limiting generalizability to other populations. Fourth, since the precise duration of ART was unknown, the effect of ART duration on fibrosis changes is unclear. Given differences in tissue penetration with INSTIs, particularly raltegravir [47] , and potential differences in local or circulating inflammatory profiles [48] [49] [50] , the effects of INSTI imbalance between arms (48% in the telmisartan arm and 0% in the control arm) cannot fully be elucidated in this pilot study. Whether telmisartan penetrated the fibrotic tissues sufficiently to effect a change is unknown, as tissue-level telmisartan concentrations are not available. Finally, the lack of statistical significance in some outcome measures and the number of inadequate and missed biopsy specimens also suggest that similar studies will need to enroll more participants.
Nonetheless, this study is the first to document the presence of abdominal adipose tissue fibrosis in HIV-infected persons outside of obesity or clinical lipodystrophy. This study was also the first clinical trial involving participants with treated HIV infection and longitudinal lymph node and adipose tissue biopsies, demonstrating the feasibility of such studies. It is the first study to document improvements in adipose tissue fibrosis and suggest possible improvements in lymph node fibrosis with continued ART alone, indicating that tissue-level inflammation may be minimized sufficiently to allow wound healing with chronic, sustained virologic suppression.
In summary, in this pilot study, continued suppressive ART decreased subcutaneous abdominal adipose tissue fibrosis and may decrease lymph node fibrosis. The addition of telmisartan, an ARB and PPAR-γ agonist, did not provide additional benefit. Analysis of tissue-level and systemic inflammatory and immunologic environments may help determine the specific mechanisms contributing to this change and/or identify future therapeutic opportunities.
Notes
